Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.
about
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsUpdate on human herpesvirus 6 biology, clinical features, and therapyOral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Human cytomegalovirus terminase as a target for antiviral chemotherapy.Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir.Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.Acceleration of allograft failure by cytomegalovirusImpairment of cytomegalovirus-specific cellular immune response as a risk factor for cytomegalovirus disease in transplant recipients.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients.Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation.Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.Peripheral blood leukocytes and serum nested polymerase chain reaction are complementary methods for monitoring active cytomegalovirus infection in transplant patients.Ganciclovir-resistant cytomegalovirus in organ transplant recipients.Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
P2860
Q24200991-9E6ECDDF-9565-4C93-956F-F2D2DE79B87CQ24244606-55903936-DA8C-47E7-B478-44D86F841F2AQ24557543-5F836E4F-6A20-4500-A3F5-8FF3A15F8CBCQ34481742-672D0918-3C4A-474C-A240-C23089B4BF5CQ34580776-CEA0F0C7-0494-4286-9B19-901D2A338351Q34918468-AE9D2D7E-3C4A-4278-8F4F-8D3CD20F34BCQ36006091-6AF8AE07-9D55-40F4-8071-0AAAC1038EA6Q36043642-08AB0768-B336-442A-A621-9504B157C76EQ36433529-C01CED90-5E65-467B-89A9-37375717567FQ37024817-D5898963-901F-4D08-AD38-568BE732E13EQ38779846-EA89342B-8409-4335-BB7E-B22AEA149773Q38875887-3D14CC51-E877-4619-BB18-0E58B5A4A874Q39502888-FAA85C10-CE57-4D6E-BA41-E0DA780E4952Q39628374-AC4CA941-7BB2-4F16-B64B-95E6F7889A57Q40115981-258858A3-03F9-430B-9410-76310F6FCF81Q40956620-A441ED8F-AE29-4078-B612-92C9FE1D12A5Q42039829-726C9CB0-F6C3-4948-96D1-327DD0F5AAE5Q44000196-D024E526-2E8D-48CB-91A7-35A511C40699Q44407642-D360EF01-21C4-439D-8B5A-323B5B99EF09Q44441505-27364AAD-8721-4EA7-A03B-C1B13E5816E4Q44461493-91E9FE7F-28DA-4081-9809-A468D57900ADQ46963345-B04A742D-021F-4BF9-AA65-27E8A598068B
P2860
Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Prophylaxis for CMV should not ...... n solid organ transplantation.
@ast
Prophylaxis for CMV should not ...... n solid organ transplantation.
@en
Prophylaxis for CMV should not ...... n solid organ transplantation.
@nl
type
label
Prophylaxis for CMV should not ...... n solid organ transplantation.
@ast
Prophylaxis for CMV should not ...... n solid organ transplantation.
@en
Prophylaxis for CMV should not ...... n solid organ transplantation.
@nl
prefLabel
Prophylaxis for CMV should not ...... n solid organ transplantation.
@ast
Prophylaxis for CMV should not ...... n solid organ transplantation.
@en
Prophylaxis for CMV should not ...... n solid organ transplantation.
@nl
P2860
P356
P1476
Prophylaxis for CMV should not ...... n solid organ transplantation.
@en
P2093
P2860
P356
10.1002/RMV.310
P577
2001-03-01T00:00:00Z